(Q42930136)

11 November 2017

title

Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial (English)

1 reference

Parkinson's disease dementia

11 November 2017

0 references

1 reference

1 reference

1 reference

dementia with Lewy bodies

inferred from title

1 reference

5

Eduardo Tolosa

1 reference

11 November 2017

2

Magda Tsolaki

1 reference

11 November 2017

Ubaldo Bonuccelli

3

1 reference

ORCID Public Data File 2021

Andres Ceballos-Baumann

7

object named as

Andrés Ceballos-Baumann

1 reference

11 November 2017

10

Roy Jones

1 reference

11 November 2017

Murat Emre

1

1 reference

11 November 2017

Alain Destée

4

1 reference

11 November 2017

Alexandra Kutzelnigg

6

1 reference

11 November 2017

Slobodan Zdravkovic

8

1 reference

11 November 2017

Anna Bladström

9

1 reference

11 November 2017

11018 Study Investigators

11

1 reference

11 November 2017

publication date

20 August 2010

1 reference

11 November 2017

1 reference

11 November 2017

volume

9

1 reference

11 November 2017

issue

10

1 reference

11 November 2017

page(s)

969-977

1 reference

DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers

11 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Risk of dementia in Parkinson's disease: a community-based, prospective study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

A systematic review of prevalence studies of dementia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Clinical diagnostic criteria for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Visual perception in Parkinson disease dementia and dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Imaging beta-amyloid burden in aging and dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Rivastigmine for dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha-synuclein/phospholipase C (PLCbeta1) interactions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

The use of memantine in dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Randomized controlled trial of memantine in dementia associated with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Memantine in moderate-to-severe Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Role of cholinesterase inhibitors in Parkinson's disease and dementia with Lewy bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2810%2970194-0

7 January 2021

10.1016/S1474-4422(10)70194-0

Identifiers

DOI

1 reference

11 November 2017

1 reference